{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:13:26Z","timestamp":1776230006506,"version":"3.50.1"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dyslipidemia is common in chronic kidney disease (CKD), including immunoglobulin A (IgA) nephropathy (IgAN), and may be associated with renal prognosis; however, the value of dyslipidemia in IgAN remains insufficiently assessed. The objective of our study was to investigate clinicopathological characteristics and renal outcomes in IgAN patients with dyslipidemia and to evaluate the prognostic value of lipid abnormalities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cohort study included 458 primary IgAN patients for a retrospective analysis. The clinicopathological features and renal outcomes were recorded. In univariate and multivariate models, the associations between dyslipidemia and renal outcomes, as well as dyslipidemia-associated pathological features, were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients with dyslipidemia\u2014defined as a total cholesterol of \u22655.2\u202fmmol\/L, triglycerides of \u22651.7\u202fmmol\/L, or low-density lipoprotein cholesterol [LDL-C] of \u22653.4\u202fmmol\/L\u2014exhibited elevated complement levels and worse clinical characteristics with regard to blood pressure, proteinuria, kidney function, and glomerulosclerosis; tubular atrophy\/interstitial fibrosis (T1\u20132), crescents, and vascular lesions were more common. A multivariate logistic regression revealed that T1\u20132 and arterial intimal fibrosis were significantly associated with dyslipidemia. After a mean follow-up of 54.7\u202fmonths, dyslipidemia (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.001), especially abnormalities in total cholesterol (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.016) and triglycerides (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.001), was significantly associated with poorer renal survival, and renal survival was not improved after lipid-lowering therapies. In addition to estimated glomerular filtration rate (eGFR) and arterial intimal fibrosis, dyslipidemia is an independent predictor for renal survival in multivariate Cox analyses (model 1: HR, 2.206; 95% CI, 1.127\u20134.317;\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.021; model 2: HR, 2.085; 95% CI, 1.059\u20134.106;\n                      <jats:italic>p<\/jats:italic>\n                      =\u202f0.034).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>IgAN patients with dyslipidemia exhibited more severe clinicopathological features. Tubular atrophy\/interstitial fibrosis and arteriosclerosis\/arteriolosclerosis were closely associated with dyslipidemia. Dyslipidemia not only indicates adverse renal outcomes but also serves as an independent prognostic predictor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1695909","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:39:35Z","timestamp":1776227975000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Renal outcomes and predictive value of dyslipidemia in patients with IgA nephropathy: a retrospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Yiping","family":"Ruan","sequence":"first","affiliation":[{"name":"Department of Nephrology, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoyun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Computer Engineering, Fuzhou University Zhicheng College","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuyuan","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fayang","family":"Lian","sequence":"additional","affiliation":[{"name":"Epidemiology and Clinical Research Unit, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guokai","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lanting","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejing","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.amjms.2020.10.003","article-title":"IgA nephropathy: an interesting autoimmune kidney disease","volume":"361","author":"Rajasekaran","year":"2021","journal-title":"Am J Med Sci"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000520039","article-title":"IgA nephropathy: a Chinese perspective","volume":"2","author":"Zhang","year":"2022","journal-title":"Glomerular Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41581-018-0072-9","article-title":"Lipid management in patients with chronic kidney disease","volume":"14","author":"Ferro","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1053\/j.ajkd.2016.01.016","article-title":"Effect of statins on kidney disease outcomes: a systematic review and meta-analysis","volume":"67","author":"Su","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1037618","DOI":"10.3389\/fnut.2022.1037618","article-title":"Serum triglycerides level is independently associated with renal outcomes in patients with non-dialysis chronic kidney disease: results from KNOW-CKD study","volume":"9","author":"Suh","year":"2022","journal-title":"Front Nutr"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/ndt\/15.1.34","article-title":"Hypertriglyceridaemia and hyperuricaemia are risk factors for progression of IgA nephropathy","volume":"15","author":"Syrj\u00e4nen","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000529822","article-title":"Clinicopathological characteristics and outcomes of immunoglobulin a nephropathy with different types of dyslipidemia: a retrospective single-center study","volume":"48","author":"Liu","year":"2023","journal-title":"Kidney Blood Press Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1007\/s11255-021-02844-4","article-title":"Hyperuricemia and hypertriglyceridemia indicate tubular atrophy\/interstitial fibrosis in patients with IgA nephropathy and membranous nephropathy","volume":"53","author":"Liu","year":"2021","journal-title":"Int Urol Nephrol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11255-019-02371-3","article-title":"The role of hypertriglyceridemia and treatment patterns in the progression of IgA nephropathy with a high proportion of global glomerulosclerosis","volume":"52","author":"Wang","year":"2020","journal-title":"Int Urol Nephrol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"708","DOI":"10.5301\/jn.5000278","article-title":"Fluctuation of serum C3 levels reflects disease activity and metabolic background in patients with IgA nephropathy","volume":"26","author":"Suzuki","year":"2013","journal-title":"J Nephrol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.molimm.2015.02.027","article-title":"The role of complement factor C3 in lipid metabolism","volume":"67","author":"Barbu","year":"2015","journal-title":"Mol Immunol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.jacl.2021.01.011","article-title":"C3 and alternative pathway components are associated with an adverse lipoprotein subclass profile: the CODAM study","volume":"15","author":"Xin","year":"2021","journal-title":"J Clin Lipidol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","article-title":"IgA nephropathy","volume":"9","author":"Stamellou","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1053\/j.ajkd.2020.03.017","article-title":"Arteriolar C4d in IgA nephropathy: a cohort study","volume":"76","author":"Faria","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejim.2023.07.007","article-title":"Clinicopathological characteristics, risk factors and prognostic value of intrarenal vascular lesions in IgA nephropathy","volume":"117","author":"Ruan","year":"2023","journal-title":"Eur J Intern Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/978-3-319-07320-0_12","article-title":"Postprandial inflammation: targeting glucose and lipids","volume":"824","author":"de Vries","year":"2014","journal-title":"Adv Exp Med Biol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"612","DOI":"10.4093\/dmj.2023.0067","article-title":"Dyslipidemia in patients with chronic kidney disease: an updated overview","volume":"47","author":"Suh","year":"2023","journal-title":"Diabetes Metab J"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1093\/eurheartj\/eht065","article-title":"Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis","volume":"34","author":"Hou","year":"2013","journal-title":"Eur Heart J"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/nu14214704","article-title":"Non-high-density lipoprotein cholesterol and progression of chronic kidney disease: results from the KNOW-CKD study","volume":"14","author":"Suh","year":"2022","journal-title":"Nutrients"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.3390\/biomedicines12061250","article-title":"Does metabolic syndrome and its components have prognostic significance for renal and cardiovascular outcomes in IgA nephropathy?","volume":"12","author":"S\u00e1gi","year":"2024","journal-title":"Biomedicine"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.numecd.2021.09.037","article-title":"Low-density lipoprotein cholesterol levels and adverse clinical outcomes in chronic kidney disease: results from the KNOW-CKD","volume":"32","author":"Lee","year":"2022","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1037773","DOI":"10.3389\/fendo.2023.1037773","article-title":"Prognostic value of low-density lipoprotein cholesterol in IgA nephropathy and establishment of nomogram model","volume":"14","author":"Tian","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e11162","DOI":"10.1161\/JAHA.118.011162","article-title":"Association between serum high-density lipoprotein cholesterol levels and progression of chronic kidney disease: results from the KNOW-CKD","volume":"8","author":"Nam","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1007\/s00467-022-05480-x","article-title":"Dyslipidemia may be a risk factor for progression in children with IgA nephropathy","volume":"37","author":"Zhuang","year":"2022","journal-title":"Pediatr Nephrol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1695909\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T04:39:41Z","timestamp":1776227981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1695909\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":24,"alternative-id":["10.3389\/fmed.2026.1695909"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1695909","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"article-number":"1695909"}}